A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)

Trial Profile

A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Dexamethasone; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-189; MK-3475-189/KEYNOTE-189
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 Jun 2017 Planned End Date changed from 1 Mar 2019 to 26 Apr 2019.
    • 22 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Oct 2016 According to Eli Lilly media release, the first results from this study could be available before the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top